Proactive Investors - Run By Investors For Investors

CytoDyn aims to be 'paradigm-shifting' in cancer management with its platform drug leronlimab

CytoDyn Inc (OTCQB:CYDY) CytoDyn CEO Nader Pourhassan and CMO Dr. Richard Pestell sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. 

The biotechnology company is focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV.

View full CYDY profile View Profile

CytoDyn Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use